In the news release issued Wednesday by The University of Tulsa over PR Newswire, we have been advised that the third sentence should read: “According to Cybersecurity Ventures, the global cost of cybercrime is set to grow from $3 trillion in 2015 to $10.5 trillion by 2025 … in order to add attribution for the source of the figures.”
University of Tulsa launches cyber research, commercialization institute with projected $75M investment
TULSA, Okla., Aug. 23, 2023 /PRNewswire/ — The University of Tulsa announced the formation of the new Oklahoma Cyber Innovation Institute to undertake groundbreaking cyber research and identify, test and commercially deploy new cyber solutions. The institute builds on the university’s educational foundation in cybersecurity to address cyber workforce development issues.
According to Cybersecurity Ventures, “the global cost of cybercrime is set to grow from $3 trillion in 2015 to $10.5 trillion by 2025. Last year, more than 700,000 jobs in this field went unfilled,” said TU Vice President for Research and Economic Development Rose Gamble. “The Oklahoma Cyber Innovation Institute will capitalize on decades of academic excellence at TU and expand research opportunities to include the expertise needed to put the findings into market.”
The growing significance of cybercrime and the deficit of cybersecurity workforce fuel the launch of the Oklahoma Cyber Innovation Institute. According to the Cybersecurity and Infrastructure Security Agency, 33% of home computers are infected with malicious software, 47% of American adults have had their personal information exposed by cyber criminals and 44% of millennials fall victim to cybercrime. Cybersecurity Ventures reported growth in cybersecurity job vacancies from 1 million openings in 2013 to 3.5 million in 2023.
TU establishes the Oklahoma Cyber Innovation Institute with an initial $24 million investment to attract top-notch cyber talent; implement workforce development pipelines involving constituencies from across the state; construct and/or renovate key facilities; launch innovative research and commercialization programs; and scale up the necessary intellectual property development, tech transfer and commercialization infrastructure in Oklahoma. Seed funding includes $12 million from the American Rescue Plan Act with matching funds from the George Kaiser Family Foundation.
OCII anticipates more than $50 million in additional funding over five years from public and private sources to support the critical challenges addressed through their faculty, staff and student researchers solving real-world issues.
“We are looking for corporate and public sector partners who want access to the best minds in the business,” said TU President Brad R. Carson. “Opportunities for sponsored cyber research, talent pipeline partnerships, facility development and/or entrepreneurial ecosystem support are all crucial.”
TU was recently ranked in the top 25 schools for cybersecurity by U.S. News and World report, tied with institutions like Harvard University. The institute will attract world-class scientists and engineers to work alongside TU’s renowned cyber faculty in the areas of digital transformation, critical infrastructure protection, autonomous systems and organizational security.
Players Previously Announced Include: Michael Beasley, Jodie Meeks, Jordan Crawford, Mike Taylor, Donte Green, Glen Rice, Earl Clark, Ryan Carter, Joe Johnson, Jeremy Pargo, Leandro Barbosa, Gerald Green, Elijah Stewart, Royce White, Frank Nitty & Jason Richardson
LOS ANGELES, Aug. 26, 2023 /PRNewswire/ — Jaylen Brown is set to play in the highly anticipated BIG3 All-Star Game in London, UK at the O2 Arena on Saturday, August 26th. Brown will be playing to support local charity, London Youth which aims to support and improve the lives of London’s youth through their network of community organizations. BIG3 will match Jaylen’s donation to the organization to further bring awareness to the global causes Jaylen supports.
Brown’s long-term focus and commitment off the court for his community work is evident, with his Bridge Program, a learning and leadership initiative to help cultivate the next generation of leaders in science and technology for young people from traditional marginalized minority communities, developed by his 7uice Foundation.
The festivities will be aired on CBS at 12:00PM ET with the All-Star Game at 6:00PM BST and the Championship following at 7:00PM BST.
Upcoming CBS airing schedule below: 12:00 pm EST – Celebrity Game 1:00 pm EST – All Star Game 2:00 pm EST – Championship Game
Tickets for the BIG3 All-Star Game are available at big3.com
ABOUT BIG3: BIG3 (BIG3.com) is who we are FIREBALL3 is what we play. It’s not your grandfather’s 3-on-3. The premier global BIG3 league features many of the greatest, most popular, and skilled professional athletes of all time. Founded by producer, actor, and music legend Ice Cube and entertainment executive Jeff Kwatinetz, the BIG3 combines highly competitive, physical, fast game experiences and incredible fan experiences. In 2023, the BIG3 was named “Best in Web3” by Sports Business Journal for the league’s groundbreaking Web3 Project, Forever Experience Action Tokens (FEATs), offering utility and ownership-like value in BIG3 teams via blockchain technology.
Players Previously Announced Include: Michael Beasley, Jodie Meeks, Jordan Crawford, Mike Taylor, Donte Green, Glen Rice, Earl Clark, Ryan Carter, Joe Johnson, Jeremy Pargo, Leandro Barbosa, Gerald Green, Elijah Stewart, Royce White, Frank Nitty & Jason Richardson
LOS ANGELES, Aug. 26, 2023 /PRNewswire/ — Jaylen Brown is set to play in the highly anticipated BIG3 All-Star Game in London, UK at the O2 Arena on Saturday, August 26th. Brown will be playing to support local charity, London Youth which aims to support and improve the lives of London’s youth through their network of community organizations. BIG3 will match Jaylen’s donation to the organization to further bring awareness to the global causes Jaylen supports.
Brown’s long-term focus and commitment off the court for his community work is evident, with his Bridge Program, a learning and leadership initiative to help cultivate the next generation of leaders in science and technology for young people from traditional marginalized minority communities, developed by his 7uice Foundation.
The festivities will be aired on CBS at 12:00PM ET with the All-Star Game at 6:00PM BST and the Championship following at 7:00PM BST.
Upcoming CBS airing schedule below: 12:00 pm EST – Celebrity Game 1:00 pm EST – All Star Game 2:00 pm EST – Championship Game
Tickets for the BIG3 All-Star Game are available at big3.com
ABOUT BIG3: BIG3 (BIG3.com) is who we are FIREBALL3 is what we play. It’s not your grandfather’s 3-on-3. The premier global BIG3 league features many of the greatest, most popular, and skilled professional athletes of all time. Founded by producer, actor, and music legend Ice Cube and entertainment executive Jeff Kwatinetz, the BIG3 combines highly competitive, physical, fast game experiences and incredible fan experiences. In 2023, the BIG3 was named “Best in Web3” by Sports Business Journal for the league’s groundbreaking Web3 Project, Forever Experience Action Tokens (FEATs), offering utility and ownership-like value in BIG3 teams via blockchain technology.
NEW YORK, Aug. 26, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $100,000 investing in BioXcel stock or options between December 15, 2021 and June 28, 2023and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BTAI.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
On December 15, 2021, the Company announced that it had initiated a program to evaluate BXCL501 for the treatment of acute agitation associated with Alzheimer’s disease. The Company announced that the program consisted of two randomized, double-blind, placebo-controlled studies: TRANQUILITY II and TRANQUILITY III. The studies were purportedly designed to evaluate the safety and efficacy of BXCL501 in adults 65 years and older across the range of illness including mild, moderate, and severe dementia in assisted living or residential facilities and nursing homes.
However, on June 29, 2023, before the market opened, BioXcel disclosed that its principal investigator for the Phase 3 TRANQUILITY II clinical trial had failed to “adhere to the informed consent form approved by the Institutional Review Board” for some subjects and failed to maintain adequate case histories for certain patients whose records were reviewed by the Food and Drug Administration (“FDA”). The Company further disclosed that the same principal investigator “may have fabricated” email correspondence purporting to demonstrate that the investigator timely submitted to the Company’s pharmacovigilance safety vendor a report of a serious adverse event (“SAE”) and purporting to show that the vendor had confirmed receipt. BioXcel further disclosed that the fabricated email correspondence was provided to the FDA during an on-site inspection in December 2022. The Company further disclosed that it was in the process of conducting an investigation into protocol adherence and data integrity at the principal investigator’s trial site and was in the process of retaining an independent third party to audit the data collected at the site. The Company also disclosed that the foregoing “may impact the timing of the Company’s development plans for, and prospects for regulatory approval of, BXCL501 for the acute treatment of agitation associated with dementia in patients with probable Alzheimer’s disease.”
On this news, BioXcel’s stock price fell $11.28 per share, or 63.8%, to close at $6.39 per share on June 29, 2023, on unusually heavy trading volume.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company lacked adequate internal controls over protocol adherence and data integrity; (2) that, as a result, the Company’s principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (3) that the Company’s principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the FDA; (4) that the Company’s principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; (5) that the foregoing would negatively impact the Company’s ability to obtain regulatory approval of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer’s disease; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding BioXcel’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FAYETTEVILLE, Ark., Aug. 26, 2023 /PRNewswire/ — Authorities are racing to determine the source of an E. coli outbreak in which nearly 100 University of Arkansas students and staff may have contracted E. coli. Four people have been hospitalized. At least one of those hospitalized has acute kidney failure.
E. coli infections can cause a type of acute kidney failure called Hemolytic uremic syndrome or “HUS”. HUS is a severe, life-threatening condition that results in an abnormal destruction of red blood cells and can lead to kidney failure. It occurs in about 10% of those who become infected with O157: H7 or any other Shiga toxin-producing E. coli.
The University of Arkansas and the Arkansas Department of Health are trying to identify the source of the University of Arkansas Ecoli outbreak, which they believe started more than a week ago. Students at the University of Arkansas moved into dorms just last week and returned to class Monday.
“The scary thing about this outbreak is there’s nothing you can do to tell whether the food that you are served is safe. You can’t taste, smell, or see E. coli. Food that is contaminated with E. coli may look, smell, and taste just like any other food. This is why it’s critical that restaurants and cafeterias who make and sell our food, ensure the food is safe before they sell it,” said E. coli food poisoning lawyer Jory Lange.
Record-Breaking Food Poisoning Lawyer
Jory Lange is one of the nation’s leading food poisoning lawyers. Jory recently won a $10 million settlement on behalf of a family who suffered life-long medical complications after getting food poisoning from a restaurant. The $10 million settlement is believed to be the largest settlement in US history on behalf of a person who developed Reactive Arthritis from food poisoning.
How The Lange Law Firm Can Help
Our mission is to help families who have been harmed by contaminated food products. When cafeterias or restaurants harm their customers in E. coli outbreaks, we use the law to hold them accountable. If you suspect that you have been infected with E. coli by food you ate and are interested in making a legal claim for compensation, we can help. Call us for a free no obligation legal consultation at (833) 330-3663 or send us an e-mail here.
About the legal team:
Jory Lange with MakeFoodSafe.com is one of the United States’ leading E. coli Lawyers, successfully representing clients across the United States in food poisoning cases from E. coli, Shigella, and Salmonella food poisoning.
NEW YORK, Aug. 26, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against RTX Corporation (“RTX” or the “Company”) (NYSE: RTX) and reminds investors of the October 2, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $100,000 investing in RTX stock or options between February 8, 2021 and July 25, 2023and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/RTX.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) the GTF engines had been affected from at least 2015-2020 by a quality control issue; (2) this quality control issue would require RTX to recall and reinspect many of its GTF engines, affecting customers and harming its business; and (3) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
On July 25, 2023, RTX issued a press release announcing an update on its Pratt & Whitney fleet. The Company stated “Pratt & Whitney has determined that a rare condition in powdered metal used to manufacture certain engine parts will require accelerated fleet inspection. This does not impact engines currently being produced. As a result, the business anticipates that a significant portion of the PW1100G-JM engine fleet, which powers the A320neo, will require accelerated removals and inspections within the next nine to twelve months, including approximately 200 accelerated removals by mid-September of this year.”
On this news, the price of RTX’s stock fell by $9.19 per share, or 10.22%, to close at $87.10 on July 25, 2023.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding RTX’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
